Abstract: The invention relates to triazole compounds of the general formula I wherein R1 is hydrogen or methyl, and R2 is C3-C4 alkyl or C1-C2 fluoroalkyl, as well as the physiologically tolerated acid addition salts of these compounds. The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.

Abstract: Triazole compounds of the following formula: where Ar1, A, B and Ar2 have the meanings given in the description, possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to dopamine D3 ligands.

Abstract: Compounds of the formula in which R1, R2 and R3 have the meanings stated in the description, are described. The novel substances are suitable for controlling diseases.

Abstract: The present invention relates to the use of pyrimidine compounds of the following formula: where R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.

Abstract: 3-substituted tetrahydropyridopyrimidinone derivatives of the formula (I) wherein the radicals have the meanings given in the Description, to a method for producing said derivatives and, to their use for producing active ingredients for drugs.

Abstract: Pyrrolylquinoxalinediones of the formula I and their tautomeric and isomeric forms, and their physiologically tolerated salts, where the variables have the following meanings: R1 hydrogen, cyclohexyl an aliphatic radical which has 1 to 4 carbon atoms and can carry the radical —COOR5, where R5 is hydrogen or C1-C4-alkyl, R2 —COOH, —COO—C1-C4, —COO—(CH2)m—Ph, —CONR6R7 and where m can be an integer from 1 to 6, R6 can be hydrogen, C1-C4-alkyl or OH and R7 can be hydrogen, C1-C4-alkyl, where all the phenyl or pyridyl rings present in R2 can also be substituted by up to 3 of the following radicals: C1-C4-alkyl, halogen, —O—C1-C4-alkyl, —OCF3, —NO2, —CN, —COOR5 or —CONHR5, R3 —CF3, —NO2, —CN, and R4 hydrogen or R3 and R4 can together be a fused-on benzene ring. The compounds are suitable as drugs for human and veterinary medicine.

Abstract: The present invention relates to triazole compounds of the following formula: where R1, R2, A, B and Ar have the meanings stated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.

Abstract: 3-Substituted 3,4,5,7-tetrahydropyrrolo[3′,4′:4,5]thieno-[2,3-d]pyrimidine derivatives of the formula I in which the substituents have the meanings stated in the description, their preparation and their use as drugs.

Abstract: Aza- and diazacyclohexane and -cyclooctane compounds of the following formula: Ar1—A—B—Ar2  (I) where Ar1, A, B and Ar2 have the meanings stated in the description have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.

Abstract: where the substituents have the meanings indicated in the description, their preparation and use as serotonin antagonists.

Abstract: The present invention relates to the use of pyrimidine compounds of the following formula: wherein R1, R2, R3, A, B and Ar have the meanings indicated in the description. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.

Abstract: Compounds of the formula I: in which R1, R2, R3 and R4 have the meanings stated in the description, are described. The novel compounds are suitable for controlling diseases.

Abstract: A 3-substituted 3,4,5,6,7,8-hexahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine compound of formula I wherein R1 is hydrogen, C1-C4-alkyl, acetyl or benzoyl, optionally substituted phenyl-C1-C4-alkyl, naphthyl-C1-C3-alkyl, phenyl-C2-C3-alkanone or a phenylcarbamoyl-C2-alkyl, R2 is optionally substituted phenyl, pyridyl, pyrimidyl or pyrazinyl, or an optionally substituted bicyclus wherein one of the two fused rings is a phenyl, a pyridyl, a pyrimidyl or a pyrazinyl ring, A is NH or oxygen, B is hydrogen or methyl, C is hydrogen, methyl or hydroxyl, X is nitrogen, Y is CH2, CH2—C2, CH2—C2—CH2 or CH2—CH, Z is nitrogen, C or CH, and the linkage between Y and Z is a single or a double bond, and n is 2, 3 or 4, or a physiologically tolerated salt thereof, and compositions comprising them and their use as antagonists of 5HT1B and 5HT1A and for the treatment of depression and related disorders.

Abstract: Aza- and diazacyclohexane and -cyclooctane compounds of the following formula: Ar1—A—B—Ar2  (I) where Ar1, A, B and Ar2 have the meanings stated in the description have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders which respond to dopamine D3 ligands.

Abstract: Compounds of the formula I ##STR1## in which the substituents have the meanings stated in the description, and their preparation are described. The novel compounds are suitable for controlling diseases.

Abstract: Compounds of the formula ##STR1## where A-B-D, R.sup.1, R.sup.2 and R.sup.3 have the meanings stated in the description, and their preparation are described. The compounds are suitable for controlling diseases.

Abstract: Abstract of the Disclosure: Compounds of the formula I ##STR1## where R.sup.1, R.sup.2, n , R.sup.3, A, X, Y and Z have the meanings stated in the description, and the preparation thereof are described. The novel compounds are suitable for controlling diseases , i.e., as neuroleptics, antidepressants, sedatives, hypnotics, CNS protectives or muscle relaxants.

Abstract: Benzofurancarboxamides having basic substituents, of the formula I ##STR1## in which R.sup.1 and X have the meanings stated in the description, a process for the preparation thereof, and therapeutic agents containing them.

Abstract: Aminoalkyl-substituted 2-amino-1,3,4-thiadiazoles of the formula ##STR1## where n and A have the meanings stated in the description, and the preparation thereof are described. The compounds are suitable for controlling diseases.

Abstract: Aminoalkyl-substituted 5-mercaptothiazoles of the formula ##STR1## where R.sup.1, n and A have the meanings stated in the description, and the preparation thereof are described.The compounds are suitable for controlling diseases.